SPT (1789) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 神隆

SPT (1789) reported revenue of NT$163.3 million for Oct 2026, -47.4% year on year and -47.2% from the previous month. Revenue for Jan–Oct 2026 was NT$2.2 billion (-11.0% year on year).

In Oct 2026, it ranked No. 50 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$227.7 million24/10Nov 2024 NT$213.6 millionDec 2024 NT$595.1 millionJan 2025 NT$207.6 millionFeb 2025 NT$164.2 million25/02Mar 2025 NT$314.6 millionApr 2025 NT$226.6 millionMay 2025 NT$262.5 millionJun 2025 NT$258.4 million25/06Jul 2025 NT$199.4 millionAug 2025 NT$344.7 millionSep 2025 NT$177.4 millionOct 2025 NT$310.7 million25/10Nov 2025 NT$209.1 millionDec 2025 NT$488.3 millionJan 2026 NT$127 millionFeb 2026 NT$207.5 million26/02Mar 2026 NT$325.2 millionApr 2026 NT$255 millionMay 2026 NT$175.2 millionJun 2026 NT$248.3 million26/06Jul 2026 NT$185.4 millionAug 2026 NT$199.3 millionSep 2026 NT$309.4 millionOct 2026 NT$163.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$163.3 million-47.4%-47.2%
Sep 2026NT$309.4 million+74.4%+55.3%
Aug 2026NT$199.3 million-42.2%+7.5%
Jul 2026NT$185.4 million-7.1%-25.3%
Jun 2026NT$248.3 million-3.9%+41.7%
May 2026NT$175.2 million-33.2%-31.3%
Apr 2026NT$255 million+12.5%-21.6%
Mar 2026NT$325.2 million+3.4%+56.8%
Feb 2026NT$207.5 million+26.3%+63.3%
Jan 2026NT$127 million-38.8%-74.0%
Dec 2025NT$488.3 million-18.0%+133.5%
Nov 2025NT$209.1 million-2.1%-32.7%
Oct 2025NT$310.7 million+36.4%+75.1%
Sep 2025NT$177.4 million-33.3%-48.5%
Aug 2025NT$344.7 million+62.7%+72.8%
Jul 2025NT$199.4 million-19.1%-22.8%
Jun 2025NT$258.4 million-8.7%-1.6%
May 2025NT$262.5 million+3.8%+15.8%
Apr 2025NT$226.6 million+0.1%-28.0%
Mar 2025NT$314.6 million-5.6%+91.6%
Feb 2025NT$164.2 million-44.5%-20.9%
Jan 2025NT$207.6 million-18.3%-65.1%
Dec 2024NT$595.1 million+4.9%+178.6%
Nov 2024NT$213.6 million-28.2%-6.2%
Oct 2024NT$227.7 million-11.8%-14.4%

Jan–Oct 2026 cumulative: NT$2.2 billion (-11.0% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: SPT vs PEC / SPT vs Lotus Pharm / SPT vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16